Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.
Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.
1457 of 1457 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
PadagisPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Palobiofarma SLPrivate | 3 assets: 1 Ph 2, 2 Ph 1 | PBF-680Phase 2 · Chronic Obstructive Pulmonary DiseasePartial signal | None on record | — | — | — | — |
PAQ Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | PT0511Phase 1 · Non-Small Cell Lung Cancer | 18 Oct 2028PT0511 · Phase 1 | — | — | — | — |
Paragon TherapeuticsPrivate | 1 asset: 1 Ph 1 | APG808Phase 1 · Chronic Obstructive Pulmonary Disease | None on record | — | — | — | — |
Partner Therapeutics, Inc.Private | 2 assets: 2 approved | Approved assets only | 31 Dec 2026Zenocutuzumab · Phase 2 | — | — | — | — |
Pathalys PharmaPrivate | 1 asset: 1 Ph 3 | UpacicalcetPhase 3 · Chronic Kidney DiseasePartial signal | 22 Feb 2032Upacicalcet · Phase 3 | — | — | — | — |
PDC*line Pharma SASPrivate | 1 asset: 1 Ph 2 | PDC*lung01Phase 1/2 · Non-Small Cell Lung CancerWeak signal | None on record | — | — | — | — |
Pediatrix TherapeuticsPrivate | 2 assets: 1 approved, 1 Ph 2 | LepzacitinibPhase 2 · Atopic Dermatitis | Apr 2027Epinephrine · Approved | — | — | — | — |
PendopharmPrivate | 1 asset: 1 approved | Approved assets only | Aug 2027palopegteriparatide · Phase 3 | — | — | — | — |
| 1 asset: 1 Ph 1 | Leucettinib-21Phase 1 · Alzheimer's DiseaseWeak signal | None on record | — | — | — | — | |
| 3 assets: 2 Ph 1, 1 other | UTAA09Phase 1 · Systemic Lupus ErythematosusWeak signal | 1 Apr 2027UTAA17 · Phase na | — | — | — | — | |
Phanes TherapeuticsPrivate | 1 asset: 1 Ph 2 | MavrostobartPhase 1/2 · Non-Small Cell Lung Cancer | Dec 2027Mavrostobart · Phase 1/2 | — | — | — | — |
Pharma Two B Ltd.Private | 1 asset: 1 Ph 3 | Pramipexole/rasagiline (P2B001)Phase 3 · Parkinson's DiseaseReliable signal | None on record | — | — | — | — |
pharmaandPrivate | 3 assets: 2 approved, 1 other | PanobinostatUS approval withdrawn · Multiple MyelomaPartial signal | None on record | — | — | — | — |
PharmacobioPrivate | 1 asset: 1 Ph 1 | DDN-A-0101Phase 1 · Alzheimer's DiseaseWeak signal | None on record | — | — | — | — |
PharmacosmosPrivate | 1 asset: 1 approved | Approved assets only | 30 Apr 2027Ferric derisomaltose · Phase 3 | — | — | — | — |
PharmanoviaPrivate | 3 assets: 2 approved, 1 Ph 3 | Diazepam (Libervant)Phase 3 · EpilepsyWeak signal | Dec 2026Solriamfetol · Phase 3 | — | — | — | — |
PharmatrophiXPrivate | 1 asset: 1 Ph 2 | LM11A-31Phase 1/2 · Alzheimer's DiseaseWeak signal | None on record | — | — | — | — |
Phebra Pty LtdPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Pheon TherapeuticsPrivate | 1 asset: 1 Ph 1 | PHN-012Phase 1 · Non-Small Cell Lung Cancer | Sep 2027PHN-012 · Phase 1 | — | — | — | — |
| 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — | |
Phrontline BiopharmaPrivate | 1 asset: 1 Ph 1 | TJ101Phase 1 · Non-Small Cell Lung Cancer | 30 Dec 2026TJ101 · Phase 1 | — | — | — | — |
Pierre Fabre MedicamentPrivate | 7 assets: 3 approved, 3 Ph 2, 1 Ph 1 | ElticertinibPhase 1/2 · Non-Small Cell Lung Cancer | 31 Mar 2027Binimetinib · Phase 3 | — | — | — | — |
Pinnacle Biologics, Inc.Private | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Plexium, Inc.Private | 1 asset: 1 Ph 1 | PLX-61639Phase 1 · Non-Small Cell Lung Cancer | Dec 2029PLX-61639 · Phase 1 | — | — | — | — |
Polpharma S.A.Private | 1 asset: 1 other | Aflibercept (Vgenfli)Age-Related Macular Degeneration | None on record | — | — | — | — |
Population CouncilPrivate | 1 asset: 1 Ph 3 | DapivirinePhase 3 · HIVReliable signal | None on record | — | — | — | — |
Poseida Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | P-BCMA-ALLO1Phase 1 · Multiple Myeloma | Mar 2029P-BCMA-ALLO1 · Phase 1 | — | — | — | — |
Priavoid GmbHPrivate | 1 asset: 1 Ph 2 | PRI-002Phase 2 · Alzheimer's DiseasePartial signal | None on record | — | — | — | — |
Prime Gene TherapeuticsPrivate | 1 asset: 1 Ph 3 | pumecitinibPhase 3 · Atopic Dermatitis | None on record | — | — | — | — |
| 1 asset: 1 Ph 1 | PLB-002Phase 1 · Non-Small Cell Lung Cancer | 30 Jun 2027PLB-002 · Phase 1 | — | — | — | — | |
Primus PharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Priothera SASPrivate | 1 asset: 1 Ph 3 | mocravimodPhase 3 · Acute Myeloid Leukemia | May 2027mocravimod · Phase 3 | — | — | — | — |
Promedico Ltd.Private | 1 asset: 1 approved | Approved assets only | Dec 2026Selinexor · Phase 2/3 | — | — | — | — |
Promontory Therapeutics Inc.Private | 1 asset: 1 Ph 2 | ImifoplatinPhase 2 · Non-Small Cell Lung CancerWeak signal | None on record | — | — | — | — |
PulmovantPrivate | 1 asset: 1 Ph 3 | MosliciguatPhase 3 · Pulmonary Hypertension Associated with Interstitial Lung Disease | Dec 2026Mosliciguat · Phase 2 | — | — | — | — |
PureIMSPrivate | 1 asset: 1 Ph 1 | Levodopa CyclopsPhase 1 · Parkinson's DiseasePartial signal | None on record | — | — | — | — |
PurGenesis TechnologiesPrivate | 1 asset: 1 Ph 2 | PUR 0110Phase 2 · Atopic Dermatitis | None on record | — | — | — | — |
Pyros PharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
| 1 asset: 1 Ph 3 | Huaier GranulePhase 3 · Non-Small Cell Lung Cancer | None on record | — | — | — | — | |
Qilu PharmaceuticalPrivate | 22 assets: 14 Ph 3, 5 Ph 2, 3 Ph 1 | AfuresertibPhase 3 · HR+/HER2- Metastatic Breast CancerPartial signal | Nov 2026QLS1304 · Phase 1 | — | — | — | — |
| 1 asset: 1 Ph 2 | HS-IT101Phase 2 · Melanoma | None on record | — | — | — | — | |
QuantumCell ApSPrivate | 1 asset: 1 Ph 1 | ACD856Phase 1 · Alzheimer's DiseasePartial signal | None on record | — | — | — | — |
Quetzal TherapeuticsPrivate | 1 asset: 1 Ph 3 | Arsenic trioxide (QTX-2101)Phase 3 · Acute Myeloid Leukemia | Mar 2027Arsenic trioxide (QTX-2101) · Phase 3 | — | — | — | — |
R-PharmPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Radius PharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | Nov 2026Elacestrant · Phase 2 | — | — | — | — |
Rapa Therapeutics LLCPrivate | 1 asset: 1 Ph 2 | RAPA-201Phase 2 · Multiple MyelomaWeak signal | 1 Mar 2029RAPA-201 · Phase 2 | — | — | — | — |
Rare Disease TherapeuticsPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
ReAlta Life SciencesPrivate | 1 asset: 1 Ph 2 | PegtarazimodPhase 2 · Chronic Obstructive Pulmonary Disease | Dec 2026Pegtarazimod · Phase 2 | — | — | — | — |
RedCloud BioPrivate | 1 asset: 1 Ph 2 | H002Phase 1/2 · Non-Small Cell Lung CancerWeak signal | None on record | — | — | — | — |
RednviaPrivate | 1 asset: 1 Ph 3 | EvogliptinPhase 3 · Type 2 DiabetesReliable signal | None on record | — | — | — | — |
Regend TherapeuticsPrivate | 3 assets: 1 Ph 3, 2 Ph 1 | REGEND001Phase 3 · Chronic Obstructive Pulmonary DiseasePartial signal | 15 Feb 2027REGEND007 · Phase 1 | — | — | — | — |
| 1 asset: 1 Ph 2 | RB-ADSCPhase 2 · Alzheimer's Disease | Sep 2028RB-ADSC · Phase 1 | — | — | — | — | |
Regor PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | regor GLP-1Phase 2 · ObesityPartial signal | None on record | — | — | — | — |
Reistone BiopharmaPrivate | 3 assets: 2 Ph 3, 1 Ph 2 | RSS0393Phase 3 · PsoriasisPartial signal | 13 Dec 2026ivarmacitinib · Phase 3 | — | — | — | — |
Remedy Plan, Inc.Private | 1 asset: 1 Ph 1 | RPT1GPhase 1 · Acute Myeloid Leukemia | 1 Dec 2028RPT1G · Phase 1 | — | — | — | — |
Remix TherapeuticsPrivate | 1 asset: 1 Ph 1 | REM-422Phase 1 · Acute Myeloid Leukemia | 31 Jul 2027REM-422 · Phase 1 | — | — | — | — |
Replicor Inc.Private | 1 asset: 1 Ph 2 | REP 2139-MgPhase 2 · Chronic Hepatitis B | None on record | — | — | — | — |
Retension PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | RTN-001Phase 2 · Hypertension | Mar 2027RTN-001 · Phase 2 | — | — | — | — |
RezeraPrivate | 1 asset: 1 Ph 2 | RuvonoflastPhase 2 · ObesityPartial signal | None on record | — | — | — | — |
Rgene CorporationPrivate | 1 asset: 1 Ph 2 | BLEX 404Phase 1/2 · Non-Small Cell Lung Cancer | 30 Apr 2027BLEX 404 · Phase 2 | — | — | — | — |
Rise TherapeuticsPrivate | 1 asset: 1 Ph 1 | R-3750Phase 1 · Ulcerative Colitis | 30 Apr 2028R-3750 · Phase 1 | — | — | — | — |
| 2 assets: 1 Ph 3, 1 Ph 2 | JS105Phase 3 · HR+/HER2- Metastatic Breast Cancer | 26 Feb 2027JS105 · Phase 1/2 | — | — | — | — | |
River 2 RenalPrivate | 1 asset: 1 Ph 2 | R2R01Phase 2 · Heart FailureWeak signal | 1 Apr 2027R2R01 · Phase 2 | — | — | — | — |
Rivus PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | HU6Phase 2 · Heart FailurePartial signal | Feb 2027HU6 · Phase 2 | — | — | — | — |
Rona TherapeuticsPrivate | 3 assets: 1 Ph 2, 2 Ph 1 | RN0361Phase 1/2 · Hypertriglyceridemia | None on record | — | — | — | — |
Rondo TherapeuticsPrivate | 1 asset: 1 Ph 1 | RNDO-564Phase 1 · Non-Small Cell Lung Cancer | 28 Feb 2029RNDO-564 · Phase 1 | — | — | — | — |
Rosemont PharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
S-Evans BiosciencesPrivate | 1 asset: 1 Ph 2 | Menstrual blood-derived mesenchymal stem cells (MenSCs)Phase 1/2 | None on record | — | — | — | — |
Sairopa B.V.Private | 1 asset: 1 Ph 1 | ADU-1805Phase 1 · Non-Small Cell Lung Cancer | May 2027ADU-1805 · Phase 1 | — | — | — | — |
Salubris Biotherapeutics IncPrivate | 1 asset: 1 Ph 2 | JK08Phase 1/2 · Non-Small Cell Lung CancerWeak signal | None on record | — | — | — | — |
Samsung BioepisPrivate | 5 assets: 5 approved | Approved assets only | None on record | — | — | — | — |
Sanwa Kagaku KenkyushoPrivate | 3 assets: 2 Ph 3, 1 other | MiglitolUS approval withdrawn · Type 2 DiabetesPartial signal | 31 Mar 2027Anagliptin · Approved | — | — | — | — |
Sardocor (Medera Biopharma)Private | 1 asset: 1 Ph 2 | AAV1.SERCA2aPhase 1/2 · Heart Failure | Oct 2027AAV1.SERCA2a · Phase 1 | — | — | — | — |
Sarfez PharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
| 3 assets: 3 approved | Approved assets only | 27 Apr 2028Roflumilast (Zoryve) · Phase 3 | — | — | — | — | |
SatRxPrivate | 1 asset: 1 Ph 3 | GosogliptinPhase 3 · Type 2 DiabetesPartial signal | None on record | — | — | — | — |
Scilex BioPrivate | 1 asset: 1 Ph 2 | TisolagilinePhase 2 · Obesity | 31 Jan 2027Tisolagiline · Phase 2 | — | — | — | — |
| 1 asset: 1 Ph 1 | SNH-118110Phase 1 · Non-Small Cell Lung Cancer | 26 Jun 2027SNH-118110 · Phase 1 | — | — | — | — | |
Sciwind BiosciencesPrivate | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | ecnoglutidePhase 3 · ObesityReliable signal | 5 Jan 2027Ecnoglutide (VRB-101) · Phase 1/2 | — | — | — | — |
scPharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | $41MJun 2025 | Ended Jan 2026 | $15M |
SDK TherapeuticsPrivate | 1 asset: 1 Ph 3 | Arsenic trioxide (SDK001)Phase 3 · Acute Myeloid LeukemiaPartial signal | Jun 2027Arsenic trioxide (SDK001) · Phase 3 | — | — | — | — |
SeagenPrivate | 5 assets: 2 approved, 2 Ph 3, 1 Ph 1 | Fetrastobart vedotinPhase 3 · Non-Small Cell Lung Cancer | 5 Jan 2028Fetrastobart vedotin · Phase 1 | — | — | — | — |
Seanergy DermatologyPrivate | 1 asset: 1 Ph 1 | SNG100Phase 1 · Atopic DermatitisWeak signal | None on record | — | — | — | — |
Second Life TherapeuticsPrivate | 1 asset: 1 Ph 2 | SL-28Phase 1/2 · Non-Small Cell Lung Cancer | 1 Jan 2027SL-28 · Phase 1/2 | — | — | — | — |
Secretome TherapeuticsPrivate | 1 asset: 1 Ph 1 | STM01Phase 1 · Heart Failure | None on record | — | — | — | — |
Seismic PharmaPrivate | 1 asset: 1 Ph 3 | IstaroximePhase 2/3 · Heart FailurePartial signal | Dec 2028Istaroxime · Phase 2/3 | — | — | — | — |
Seismic TherapeuticPrivate | 1 asset: 1 Ph 1 | S-4321Phase 1 · Psoriatic Arthritis | Sep 2027S-4321 · Phase 1 | — | — | — | — |
selectION TherapeuticsPrivate | 1 asset: 1 Ph 1 | si-544Phase 1 · PsoriasisPartial signal | None on record | — | — | — | — |
ServierPrivate | 6 assets: 2 approved, 2 Ph 3, 2 Ph 2 | TeneligliptinPhase 3 · Type 2 DiabetesReliable signal | 31 Dec 2026Ivosidenib · Phase 1 | — | — | — | — |
SFA TherapeuticsPrivate | 1 asset: 1 Ph 3 | SFA-002Phase 2/3 · Psoriasis | None on record | — | — | — | — |
| 1 asset: 1 Ph 3 | F182112Phase 3 · Multiple Myeloma | 31 Dec 2027F182112 · Phase 1 | — | — | — | — | |
| 1 asset: 1 Ph 2 | ALK202Phase 2 · Non-Small Cell Lung Cancer | Dec 2027ALK202 · Phase 1 | — | — | — | — | |
| 2 assets: 2 Ph 2 | BW-00112Phase 2 · Hypertriglyceridemia | 26 Apr 2027BW-20829 · Phase 2 | — | — | — | — | |
| 1 asset: 1 Ph 3 | Edaravone (TTYP01)Phase 3 · Acute Ischemic Stroke | 23 Oct 2028Edaravone (TTYP01) · Phase 2 | — | — | — | — | |
| 2 assets: 2 Ph 1 | BZE2204Phase 1 · Systemic Lupus Erythematosus | 31 Dec 2026CD19/CD20/BCMA CAR-T (Shanghai Cell Therapy Group) · Phase 1 | — | — | — | — | |
| 1 asset: 1 Ph 1 | Evategrel (CG-0255)Phase 1 · Atherosclerotic Cardiovascular Disease | None on record | — | — | — | — | |
| 1 asset: 1 Ph 2 | BafisontamabPhase 2 · Advanced Metastatic Colorectal CancerWeak signal | 30 Dec 2027Bafisontamab · Phase 2 | — | — | — | — | |
| 1 asset: 1 Ph 3 | Sodium oligomannatePhase 3 · Alzheimer's DiseaseReliable signal | None on record | — | — | — | — | |
Shanghai HEP PharmaceuticalPrivate | 1 asset: 1 Ph 3 | hepalatidePhase 3 · Chronic Hepatitis Delta | Jun 2028hepalatide · Phase 3 | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.